Intifyrex-Taj 0.75mg Injection
Prescription Required
Product introduction
Intifyrex-Taj 0.75mg Injection is a blood thinner which prevents formation of harmful blood clots. It is used in the treatment of a heart attack and also prevents the clotting of blood in the heart during an angioplasty (procedure to improve blood flow to the heart).
Intifyrex-Taj 0.75mg Injection is used to prevent blood flow complications during an angioplasty and even in general
Intifyrex-Taj 0.75mg Injection is used to prevent blood flow complications during an angioplasty and even in general
Uses of Intifyrex-Taj Injection
- Prevention of Blood clots
- Prevention of Heart attack
Benefits of Intifyrex-Taj Injection
In Prevention of Blood clots
Intifyrex-Taj 0.75mg Injection prevents new blood clots from forming and prevents the existing ones from getting bigger. It works by blocking a substance in the body which is involved in blood clotting. Thus it helps your blood flow smoothly throughout the body. This can help reduce damage caused by clots in your lungs (pulmonary embolism), brain (stroke), heart (heart attack) or other blood vessels (thrombosis).
In Prevention of Heart attack
It prevents blood from clotting inside the veins and arteries. This helps the blood flow freely around your body thereby preventing a heart attack or stroke (or deep vein thrombosis or pulmonary embolism). Follow your doctor’s instructions carefully and make appropriate lifestyle changes (such as eating healthy and staying active) to maximize the effectiveness of this medicine.
Side effects of Intifyrex-Taj Injection
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Intifyrex-Taj
- Bleeding
- Decreased blood pressure
How to use Intifyrex-Taj Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Intifyrex-Taj 0.75mg Injection. Please consult your doctor.
Pregnancy
SAFE IF PRESCRIBED
Intifyrex-Taj 0.75mg Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Breast feeding
CAUTION
Intifyrex-Taj 0.75mg Injection should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Driving
NOT RELEVANT
Not relevant, as Intifyrex-Taj 0.75mg Injection is intended for use in hospitalised patients.
Kidney
CAUTION
Intifyrex-Taj 0.75mg Injection should be used with caution in patients with kidney disease. Dose adjustment of Intifyrex-Taj 0.75mg Injection may be needed. Please consult your doctor.
Use of Intifyrex-Taj 0.75mg Injection is not recommended in patients with severe kidney disease.
Use of Intifyrex-Taj 0.75mg Injection is not recommended in patients with severe kidney disease.
Liver
CONSULT YOUR DOCTOR
There is limited information available on the use of Intifyrex-Taj 0.75mg Injection in patients with liver disease. Please consult your doctor.
Use of Intifyrex-Taj 0.75mg Injection is not recommended in patients with severe liver disease.
Use of Intifyrex-Taj 0.75mg Injection is not recommended in patients with severe liver disease.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
No substitutes found for this medicine
Quick tips
- It is usually given by your nurse or doctor as an infusion (drip) into a vein.
- It increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails or using sharp objects.
- Notify your doctor if you see blood in your vomit, urine or stool (black, tarry stools or bright red blood).
Fact Box
Chemical Class
Amino acids, Peptides analogues
Habit Forming
No
Therapeutic Class
BLOOD RELATED
Action Class
Glycoprotein IIb/IIIa inhibitors
Patient concerns
FAQs
Can the use of Intifyrex-Taj 0.75mg Injection increase the risk of bleeding?
Yes, Intifyrex-Taj 0.75mg Injection increases the risk of bleeding. Always be careful while doing activities that may cause an injury or bleeding. Tell your doctor immediately if you notice any abnormal bruising or bleeding.
What medicines should I avoid while taking Intifyrex-Taj 0.75mg Injection?
Intifyrex-Taj 0.75mg Injection can interact with several medicines. Do not take any medicine without talking to your doctor.
When will I feel better after taking Intifyrex-Taj 0.75mg Injection?
Intifyrex-Taj 0.75mg Injection reduces your risk of developing blood clots in the blood vessels of your leg, lungs, heart and brain. You may not feel any difference after taking Intifyrex-Taj 0.75mg Injection. However, keep taking this medicine as prescribed by your doctor because you will still be getting its full benefits.
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Weitz JI. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. p. 871.
- Fox KA, White HD, Gersh BJ, et al. Antithrombotic Agents: Platelete Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In: Opie LH, Gersh BJ, editors. Drugs for the Heart. 8th ed. Philadelphia, Pennsylvania: Elsevier Saunders; 2013. pp. 355-56.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 485-46.
- Eptifibatide. Ferentino, Italy: Patheon Italia S.p.A.; 1998 [revised Mar. 2013]. [Accessed 18 Mar. 2019] (online) Available from:
- Drugs.com. Eptifibatide Pregnancy and Breastfeeding Warnings. [Accessed 18 Mar. 2019] (online) Available from:
- Central Drugs Standard Control Organisation (CDSCO). Eptifibatide. [Accessed 18 Mar. 2019] (online) Available from:
Marketer details
Name: Taj Pharma India Ltd
Address: first floor, 15-6-108 afzal gunj, hyderabad, telangana 500012
Country of origin: India
Lab tests offered by us
Related/Popular tests
MRP
₹10540
Inclusive of all taxes
100.0 ml in 1 vial
SOLD OUT